| zibotentan (ZD4054) / AstraZeneca |
NCT06087835: Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) |
|
|
| Active, not recruiting | 3 | 1760 | Europe, Canada, Japan, US, RoW | Zibotentan/Dapagliflozin, Dapagliflozin | AstraZeneca | Chronic Kidney Disease With High Proteinuria | 01/27 | 01/27 | | |
ACTRN12618000021279: The anti-anginal effect of Zibotentan in the Coronary Slow Flow Phenomenon (CSFP) |
|
|
| Completed | 2/3 | 50 | | | The University of Adelaide, AstraZeneca Pty Ltd | Coronary Slow Flow Phenomenon | | | | |
2008-002686-30: Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease |
|
|
| Ongoing | 2 | 30 | Europe | ZD4054, | Christie Hospital NHS Foundation Trust | Prostate cancer | | | | |
2018-004393-10: Precision medicine with zibotentan in microvascular angina (PRIZE) |
|
|
| Not yet recruiting | 2 | 356 | Europe | Zibotentan, ZD4054, Tablet | NHS Greater Glasgow & Clyde, University of Glasgow, Medical Research Council, AstraZeneca UK Ltd | Microvascular Angina and impaired exercise intolerance., Microvascular angina refers to disease in the small blood vessels, associated with both a reduced quality of life and often-repeated acute hospital admissions or long-term clinic attendance, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2021-001324-18: A Study to Assess the Effects of the drugs Zibotentan and Dapagliflozin in Patients with Elevated Levels of Protein in Urine |
|
|
| Not yet recruiting | 2 | 38 | Europe | zibotentan, Dapagliflozin, ZD4054, Dapagliflozin, Capsule, hard, Tablet, Forxiga | University Medical Center Groningen, Astra Zeneca | Patients with elevated Albuminuria, Patients with protein in the urine, Diseases [C] - Hormonal diseases [C19] | | | | |
| Completed | 2 | 542 | Europe, Canada, Japan, US, RoW | Zibotentan, Dapagliflozin, Placebo | AstraZeneca, AstraZeneca AB | Chronic Kidney Disease | 06/23 | 06/23 | | |
| Completed | 2 | 225 | Europe | Zibotentan, Placebo oral tablet | NHS Greater Glasgow and Clyde, University of Glasgow, King's College London, University of Oxford, Oxford University Hospitals NHS Trust, University of Cambridge, Papworth Hospital NHS Foundation Trust, Blackpool Teaching Hospitals NHS Foundation Trust, Royal Free Hospital NHS Foundation Trust, AstraZeneca UK Ltd, Siemens Healthcare Ltd | Microvascular Angina | 06/23 | 06/23 | | |
ZEAL UNLOCK, NCT06269484: A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK |
|
|
| Recruiting | 2 | 66 | Europe, Japan, US, RoW | Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin | AstraZeneca | Liver Cirrhosis | 01/25 | 01/25 | | |
ZODIAC, NCT05570305: Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria |
|
|
| Enrolling by invitation | 2 | 38 | Europe, Canada, US | Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan | University Medical Center Groningen, AstraZeneca | Chronic Kidney Diseases | 04/24 | 09/24 | | |
| Recruiting | 2 | 195 | Europe, Canada, US, RoW | Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part A: zibotentan (dose B) + dapagliflozin, Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet), Part B: placebo (matching zibotentan capsule) + dapagliflozin, Part B: zibotentan (dose A) + dapagliflozin, Part B: zibotentan (dose B) + dapagliflozin, Part B: zibotentan (dose C) + dapagliflozin | AstraZeneca, AstraZeneca AB | Liver Cirrhosis | 01/25 | 04/25 | | |
NCT05505162: Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential. |
|
|
| Completed | 1 | 24 | US | Zibotentan, EE/LNG | AstraZeneca, Parexel | Healthy Female Participants | 01/23 | 01/23 | | |
| trans sodium crocetinate (TSC) / CervoMed, University of Virginia |
2020-002369-32: Open-label, pharmacokinetic, pharmacodynamic, ascending dose safety lead-in followed by a single-center, placebo-controlled, double-blind, adaptive, safety and efficacy, pilot study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 infected subjects |
|
|
| Not yet recruiting | 1/2 | 224 | Europe | Trans Sodium Crocetinate Crocetinate, Lyophilisate for solution for injection | Diffusion Pharmaceuticals Inc., Diffusion Pharmaceuticals Inc | COVID-19 infection, COVID-19 infection, Diseases [C] - Virus Diseases [C02] | | | | |
| SLAMF7 FPBMC / University of Virginia |
| Withdrawn | 1/2 | 18 | US | SLAMF7 FPBMC, CS-1 FPBMC | University of Virginia | Multiple Myeloma | 11/23 | 11/23 | | |
